key: cord-1047493-4ynv4jkt
authors: von Meijenfeldt, Fien A; Thålin, Charlotte; Lisman, Ton
title: Sustained prothrombotic changes in convalescent patients with COVID-19
date: 2021-06-22
journal: Lancet Haematol
DOI: 10.1016/s2352-3026(21)00146-0
sha: fdefa7c754d0e4e1826d7f47f935073c32822620
doc_id: 1047493
cord_uid: 4ynv4jkt

nan

Importantly, ex vivo hypercoagulability and hypofibrinolysis are associated with an increased risk of thrombotic events in the general population. 4, 5 It is tempting to speculate that a persistent hypercoagulable state contributes to the post-acute sequelae of SARS-CoV-2 infection (PASC; also known as long COVID) by facilitating formation of microthrombi in the pulmonary vasculature, similar to the thrombotic events proposed in stage 1 disease. 1 In this scenario, post-discharge thromboprophylaxis might benefit some convalescent patients with COVID-19, and larger controlled trials, such as the ACTIV-4 trial (NCT04498273), will provide important information on this matter. We feel that studies investigating underlying mechanisms and potential clinical consequences of sustained prothrombotic changes in convalescent patients with COVID-19 are needed, because they might have therapeutic implications.

We declare no competing interests.

COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year

Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response

Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge

Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study

Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis